News

March 11, 2026- PRESS RELEASE

Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR

November 12, 2025- ARTICLE

Zero-Contrast Balloon-Expandable Transcatheter Aortic Valve Implantation with Embolic Protection in Pure Aortic Regurgitation. Kim, Won-Keun et al. Canadian Journal of Cardiology (2025), doi: https://doi.org/10.1016/j.cjca.2025.10.034.

October 23, 2025- ABSTRACT

TCT 1022: Debris Capture and Removal Using the Emboliner Device in High Embolic-Risk Structural Heart Cases -TCT2025 San Francisco, CA

October 23, 2025- PRESS RELEASE

Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner® Embolic Protection Catheter Designed to Protect Patients from Embolic Injury During Transcatheter Aortic Valve Replacement.

September 10, 2025- EMBOLINE PRESENTATION AT 2025 LSI EUROPE

Scott Russell, Emboline’s President and CEO, presents on the overall embolic protection market and the Emboliner, Emboline’s groundbreaking full-body embolic protection device. -2025 LSI Europe

September 8, 2025- EMBOLINE PARTICIPATION ON IP MASTERCLASS PANEL

Scott Russell, Emboline’s President and CEO, discusses Emboline’s foundational IP strategy as a panelist for the IP Masterclass: Protecting What’s Yours. -2025 LSI Europe

November 26, 2024- SPONSORED SYMPOSIUM

Zero-contrast TAVI while using a novel full-body embolic protection system. PCR London Valves 2024 London, UK.

November 24, 2024- ABSTRACT

Nazif, T (2024 Nov 24) Complete Embolic Protection with Debris Capture and Removal in High-Risk Structural Heart Cases. PCR London Valves 2024 London, UK.

October 28, 2024- PRESS RELEASE

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding Embolic Protection Medical Device

May 17, 2024- ABSTRACT

de Brito, F (2024 May 17) TAVI in a severely calcified patient using a novel full-body embolic protection device (Case Presentation). euroPCR 2024 Paris, France.

April 4, 2024- PRESS RELEASE

Emboline Announces Acquisition of Significant Embolic Protection Intellectual Property Portfolio from SWAT Medical AB

March 12, 2024- PRESS RELEASE

Emboline Announces That the First One Hundred Patients Have Been Treated in the IDE Study of the Emboliner® Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR

October 26, 2023- ABSTRACT

Vora, A. (2023 Oct 23-26) Update from the PROTECT H2H Trial with Emboliner (Case Example). TCT 2023 San Francisco, CA USA.

September 16, 2023- ARTICLE

Grubman D, Ahmad Y, Leipsic JA, Blanke P, Pasupati S, Webster M, Nazif TM, Parise H, Lansky AJ (2023). Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. Am J Cardiol. 2023 Nov 15;207:28-34. doi: 10.1016/j.amjcard.2023.08.137. Epub 2023 Sep 16. PMID: 37722198.

June 29, 2023- ABSTRACT

Greenbaum, A (2023 Jun28-Jul1) Multi-generational Performance of the Emboliner Full-Body Embolic Protection Catheter for TAVI: the Complete SafePass Experience. CSI-Frankfurt 2023 Frankfurt, Germany.

June 9, 2023- ABSTRACT

Nazif, T. (2023 Jun 7-10) Performance of the New Generation Emboliner Embolic Protection Device for TAVI: the SafePass 3 Study. TVT2023 Phoenix, AZ USA.

May 19, 2023- ABSTRACT

Lansky, A. (2023 May 18-20) Full-Body Embolic Protection During Transcatheter Aortic Valve Replacement: the Protect the Head to Head Study- A Pivotal, Randomized Study Comparing the Emboliner Embolic Protection Catheter to the Sentinel CPS. SCAI 2023, Phoenix, AZ USA.

May 19, 2023- ABSTRACT

Abizaid, A. (2023 May 16-19) Full body embolic protection during transcatheter aortic valve replacement: Emboliner Embolic Protection Device, Clinical Highlights. euroPCR 2023 Paris, France.

May 9, 2023- PRESS RELEASE

Emboline Announces First Patient Treated in IDE Study of Emboliner® Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR

April 2, 2022- ARTICLE

Lansky A, White J, Stewart J, et al (2022). CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY. J Am Coll Cardiol. 2022 Mar, 79 (9_Supplement) 628. https://doi.org/10.1016/S0735-1097(22)01619-9